Cleavable Linkers for Controlled Drug Release via Beta-Elimination
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current drug-macromolecule conjugate systems face challenges in achieving controlled and tunable drug release rates, particularly for alcohol-, phenol-, and nitrogen-containing drugs, due to unpredictable enzyme activity and limited linker options that do not rely on enzymatic cleavage.
Innovation Solution
Development of cleavable linkers such as N-oxymethyl, N-(heterocyclic amino)methyl, and N-thiomethyl carbamates that facilitate beta-elimination for controlled drug release, allowing for the conjugation of a wide range of drugs with macromolecular carriers without enzyme dependence.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of moving object
If ester or carbonate linkages are used to attach drugs to macromolecular carriers, then drug release can be achieved through hydrolysis, but the release rate becomes unpredictable and difficult to adjust due to variable esterase activity
Solution Approach 1:
The patent replaces enzyme-dependent hydrolysis (biological mechanism) with beta-elimination reactions (chemical mechanism) that proceed through a defined chemical pathway. The beta-elimination mechanism involves formation of a carbamate intermediate that decomposes to release the drug, providing a predictable, tunable release rate independent of esterase activity variations.
Solution Approach 2:
The patent employs systematic modification of the R1 and R2 parameters in the linker structure (Formula I) to control the beta-elimination rate. By varying substituents at these positions, the release half-life can be precisely tuned across a wide range (hours to weeks), providing reliable and adjustable drug release kinetics.
2Stability of the object's composition
If permanent linkers are used to covalently bind drugs to macromolecules, then pharmaceutical properties such as half-life and stability are enhanced, but the drugs cannot be released and the approach is limited to extracellular targets
Solution Approach 1:
The patent creates a dynamic linker system that transitions from a stable conjugate state to a drug release state through beta-elimination. The linker maintains structural integrity during circulation (stable conjugate) but undergoes controlled chemical transformation to release the active drug, enabling both stability and release functionality in a single system.
Solution Approach 2:
The patent introduces a carbamate intermediate structure in the beta-elimination pathway that serves as a temporary carrier of the drug moiety. This intermediate allows the drug to be securely bound during transport while providing a defined chemical pathway for controlled release, bridging the gap between stable conjugation and drug liberation.
3Ease of operation
If cleavable linkers dependent on physiological enzymes are used, then drug release can occur, but the release rates vary between species and individuals and certain compartments are esterase-deficient
Solution Approach 1:
The patent segments the linker into distinct functional components (R1 group, R2 group, and the carbamate bridge) that work together through a defined chemical mechanism. This segmentation allows independent optimization of each component to achieve predictable beta-elimination kinetics that are consistent across different physiological environments and species.
4Reliability
If the linker attachment site does not hinder biological activity, then the drug remains active, but the linker cannot be attached at certain positions limiting conjugation options
Solution Approach 1:
The patent designs a universal linker platform (Formula I) that can be attached to various drugs through different functional groups (alcohols, phenols, thiols, amines) at multiple positions without compromising drug activity. The beta-elimination mechanism and carbamate intermediate structure provide consistent, predictable release behavior regardless of the specific drug or attachment position, enabling broad applicability.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables controlled and tunable release of drugs under physiological conditions, improving drug delivery by maintaining drugs in an inactive form until released, enhancing delivery to specific systems like the lymphatic system and reducing degradation.
Implementation Method 1
a drug conjugate system is described which allows for drug release through a rate-controlled, beta-elimination mechanism
Data Source
Figure 1~2B
Figure 3~4
Figure 5
AI summary
The invention relates to conjugates of macromolecular carriers and drugs comprising linkers that release the drug or a prodrug through rate-controlled beta-elimination, and methods of making and using the conjugates.